Patents by Inventor Tapas Das Gupta

Tapas Das Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10675326
    Abstract: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 9, 2020
    Inventors: Brad N. Taylor, Rajeshwari Mehta, Tohru Yamada, Craig Beattie, Tapas Das Gupta
  • Publication number: 20200172581
    Abstract: The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and also optionally comprise a cupredoxin. The present invention further relates to methods to express proteins near cancer cells. These methods may be used to express therapeutic or diagnostic proteins near cancer cells in a patient suffering from cancer or other conditions, and can also be used for diagnosing cancer in a patient. This method uses the gene for azurin from P. aeruginosa as an expression system for azurin or heterologous proteins in P. aeruginosa or heterologous cells.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 4, 2020
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10590177
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions elated to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: March 17, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10351605
    Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 16, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Craig Beattie, Tohru Yamada, Tapas Das Gupta
  • Patent number: 10266868
    Abstract: The present invention relates to cupredoxin, specifically Pseudomonas aeruginosa azurin, and/or Pseudomonas aeruginosa cytochrome c551 and their use in inhibiting of viral infection, and in particular infection of mammalian cells by the Human Immunodeficiency Virus (HIV). The invention also relates to variants and derivatives of cupredoxin and cytochrome c that retain the ability to inhibit viral infection, and in particular infection by the Human Immunodeficiency Virus (HIV). The invention also relates to research methods for studying viral and bacterial infection in mammalian cells.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: April 23, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Chang Soo Hong
  • Patent number: 10239920
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 26, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Publication number: 20190046605
    Abstract: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.
    Type: Application
    Filed: December 11, 2017
    Publication date: February 14, 2019
    Inventors: Brad N. Taylor, Rajeshwari Mehta, Tohru Yamada, Craig Beattie, Tapas Das Gupta
  • Publication number: 20180327459
    Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: November 15, 2018
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Craig Beattie, Tohru Yamada, Tapas Das Gupta
  • Publication number: 20180319848
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions elated to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
    Type: Application
    Filed: May 3, 2018
    Publication date: November 8, 2018
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Publication number: 20180319847
    Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 8, 2018
    Applicant: The Board of Trustees of the University of Illinoi s
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Yonghua Zhu
  • Patent number: 10117905
    Abstract: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 6, 2018
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 10086037
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 2, 2018
    Inventors: Tapas Das Gupta, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
  • Patent number: 10058585
    Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: August 28, 2018
    Inventors: Anita Chaudhari, Ananda Chakrabarty, Tapas Das Gupta, Arsenio Fialho, Tohru Yamada, Yonghua Zhu
  • Patent number: 10005821
    Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: June 26, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 9968685
    Abstract: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 15, 2018
    Inventors: Brad N. Taylor, Rajeshwari Mehta, Tohru Yamada, Craig Beattie, Tapas Das Gupta
  • Patent number: 9969781
    Abstract: The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and also optionally comprise a cupredoxin. The present invention further relates to methods to express proteins near cancer cells. These methods may be used to express therapeutic or diagnostic proteins near cancer cells in a patient suffering from cancer or other conditions, and can also be used for diagnosing cancer in a patient. This method uses the gene for azurin from P. aeruginosa as an expression system for azurin or heterologous proteins in P. aeruginosa or heterologous cells.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: May 15, 2018
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Patent number: 9957304
    Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof to treat cancer in mammals.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: May 1, 2018
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Yonghua Zhu
  • Publication number: 20160151452
    Abstract: The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities.
    Type: Application
    Filed: August 3, 2015
    Publication date: June 2, 2016
    Inventors: Anita Chaudhari, Ananda Chakrabarty, Tapas Das Gupta, Arsenio Fialho, Tohru Yamada, Yonghua Zhu
  • Publication number: 20160031947
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Publication number: 20150374780
    Abstract: The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The present invention further relates to compositions that may comprise cupredoxin(s), and/or variants, derivatives or structural equivalents of cupredoxins, that retain the ability to inhibit the development of premalignant lesions in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Inventors: Tapas Das Gupta, Ananda Chakrabarty